Russian drugmaker Pharmasyntez has asked the Kremlin for permission to produce a generic version of US firm Gilead Sciences' COVID-19 treatment "Remdesivir" without а patent, Russian business daily Vedomosti reported on Monday.
Follow Israel Hayom on Facebook and Twitter
Siberia-based Pharmasyntez previously approached Gilead requesting a voluntary license to produce and distribute the drug in Russia, the company's director, Vikram Punia, said.
But it was not able to produce the drug as it is protected by a patent and Gilead did not respond to a request for a voluntary license, Vedomosti reported, citing a letter sent by Punia to several Russian ministries.
Pharmasyntez did not immediately respond to a request for comment.
